TABLE 1.
Parameter or conditiona | No. (%) of patients in:
|
P | |
---|---|---|---|
Cefazolin group (n = 59) | Extended-spectrum cephalosporin group (n = 48) | ||
Age ≥ 60 yr | 31 (52.5) | 23 (47.9) | 0.63 |
Females | 18 (30.5) | 17 (35.4) | 0.59 |
Underlying illnesses | |||
Diabetes mellitus | 35 (59.3) | 22 (45.8) | 0.16 |
Liver cirrhosis | 2 (3.4) | 2 (4.2) | 0.83 |
Gall bladder stone | 6 (10.2) | 7 (14.6) | 0.49 |
Biliary tract stone | 6 (10.2) | 7 (14.6) | 0.49 |
Biliary or GI tract operation | 7 (11.9) | 4 (8.3) | 0.55 |
Peptic ulcer | 9 (15.3) | 5 (10.4) | 0.46 |
Solid-organ cancer | 4 (6.8) | 5 (10.4) | 0.50 |
Alcoholism | 5 (8.5) | 1 (2.1) | 0.15 |
Hypertension | 11 (18.6) | 10 (20.8) | 0.78 |
Vital signs | |||
BT > 38°C or < 36°C | 27 (45.8) | 22 (45.8) | 0.99 |
HR > 90/min | 30 (50.8) | 22 (45.8) | 0.61 |
RR > 20/min | 21 (35.6) | 20 (41.7) | 0.52 |
MAP < 80 mm Hg | 9 (15.3) | 11 (22.9) | 0.31 |
APACHE III score > 40 | 14 (23.7) | 14 (29.2) | 0.52 |
BT, body temperature; HR, heart rate; RR, respiratory rate; MAP, mean arterial pressure; GI, gastrointestinal. Extended-spectrum cephalosporins were ceftriaxone (n = 25), cefotaxime (n = 10), moxalactam (n = 7), cefoperazone (n = 5), and ceftazidime (n = 1)